Published in Mol Cell on April 06, 2006
mTOR signaling in growth control and disease. Cell (2012) 29.21
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
mTOR signaling at a glance. J Cell Sci (2009) 8.66
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell (2008) 6.88
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A (2008) 6.84
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science (2012) 6.69
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab (2008) 6.60
mTOR regulation of autophagy. FEBS Lett (2010) 6.59
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J (2008) 6.32
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev (2008) 5.52
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 5.22
mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci (2009) 5.04
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J (2008) 4.79
Translational control of long-lasting synaptic plasticity and memory. Neuron (2009) 4.77
Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol (2009) 4.66
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell (2006) 4.55
Targeting the mTOR signaling network for cancer therapy. J Clin Oncol (2009) 4.52
The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J (2008) 4.49
Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab (2010) 4.44
A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans (2009) 4.37
Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity (2010) 4.06
Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78
Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One (2010) 3.62
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51
The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol (2008) 3.50
An emerging role of mTOR in lipid biosynthesis. Curr Biol (2009) 3.50
AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med (2013) 3.41
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol (2008) 3.36
Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol (2009) 3.32
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26
mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol (2009) 3.22
Foxo transcription factors control regulatory T cell development and function. Immunity (2010) 3.17
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res (2011) 3.12
Regulation of immune responses by mTOR. Annu Rev Immunol (2011) 3.08
Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J (2007) 3.08
Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab (2008) 3.03
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest (2011) 3.00
TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res (2009) 2.96
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest (2011) 2.90
Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci (2009) 2.90
Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem (2010) 2.90
Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev (2008) 2.89
The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity (2010) 2.85
Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol (2008) 2.85
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
mTOR signaling and drug development in cancer. Nat Rev Clin Oncol (2010) 2.77
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol (2009) 2.67
mTOR complex 2 signaling and functions. Cell Cycle (2011) 2.66
Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes (2010) 2.65
Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis. J Physiol (2009) 2.64
Common corruption of the mTOR signaling network in human tumors. Oncogene (2008) 2.60
PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med (2012) 2.58
mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol (2009) 2.57
mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion. Dev Cell (2010) 2.56
Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One (2009) 2.54
mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A (2008) 2.50
Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest (2008) 2.40
Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem (2008) 2.38
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci (2009) 2.35
Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J Cell Biol (2009) 2.30
Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes (2010) 2.30
mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab (2011) 2.28
Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J (2007) 2.27
Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol (2008) 2.26
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene (2010) 2.22
Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci (2013) 2.22
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci (2010) 2.15
Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell (2012) 2.15
Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest (2013) 2.14
mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature (2014) 2.13
RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer (2011) 2.12
Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11
Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol (2013) 2.09
The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway. Nat Rev Microbiol (2008) 2.08
PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One (2007) 2.07
PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci (2011) 2.06
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell (2012) 2.06
mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc Natl Acad Sci U S A (2009) 2.05
MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest (2010) 2.04
mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell (2011) 2.03
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res (2008) 2.01
Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol (2014) 1.96
Physiological regulation of Akt activity and stability. Am J Transl Res (2010) 1.95
Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol (2014) 1.95
mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem (2009) 1.93
Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice. J Neurosci (2010) 1.92
Where is mTOR and what is it doing there? J Cell Biol (2013) 1.91
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol (2006) 32.51
mTOR signaling in growth control and disease. Cell (2012) 29.21
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
CellProfiler: free, versatile software for automated biological image analysis. Biotechniques (2007) 14.71
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (2008) 14.08
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell (2010) 12.24
Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Genetic screens in human cells using the CRISPR-Cas9 system. Science (2013) 10.75
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68
mTOR signaling at a glance. J Cell Sci (2009) 8.66
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science (2011) 7.55
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol (2002) 7.44
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science (2012) 6.69
A unifying model for mTORC1-mediated regulation of mRNA translation. Nature (2012) 6.44
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
The pharmacology of mTOR inhibition. Sci Signal (2009) 5.36
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21
Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc Natl Acad Sci U S A (2009) 5.15
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol (2006) 5.06
A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J (2012) 5.03
Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol (2002) 4.77
mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell (2011) 4.70
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods (2006) 4.12
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol (2003) 4.01
A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science (2013) 3.96
Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res (2010) 3.94
mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature (2010) 3.81
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78
Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell (2012) 3.77
Tumours with PI3K activation are resistant to dietary restriction. Nature (2009) 3.60
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51
An emerging role of mTOR in lipid biosynthesis. Curr Biol (2009) 3.50
An expanding role for mTOR in cancer. Trends Mol Med (2005) 3.40
Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell (2010) 3.33
mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol (2009) 3.22
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
Cancer cell metabolism: one hallmark, many faces. Cancer Discov (2012) 3.03
CellProfiler Analyst: data exploration and analysis software for complex image-based screens. BMC Bioinformatics (2008) 2.99
Systematic genome-wide screens of gene function. Nat Rev Genet (2004) 2.92
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
RNAi living-cell microarrays for loss-of-function screens in Drosophila melanogaster cells. Nat Methods (2004) 2.72
mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science (2013) 2.71
TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. Cell Metab (2012) 2.59
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature (2013) 2.46
EMRE is an essential component of the mitochondrial calcium uniporter complex. Science (2013) 2.39
Amino acids and mTORC1: from lysosomes to disease. Trends Mol Med (2012) 2.38
Regulation of mTORC1 by the Rag GTPases is necessary for neonatal autophagy and survival. Nature (2012) 2.28
Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell (2011) 2.24
Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci (2013) 2.22
Microarrays of lentiviruses for gene function screens in immortalized and primary cells. Nat Methods (2006) 2.18
Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest (2013) 2.14
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med (2014) 2.09
Building mammalian signalling pathways with RNAi screens. Nat Rev Mol Cell Biol (2006) 2.06
Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem (2005) 2.00
Rapamycin inhibits mTORC1, but not completely. Autophagy (2009) 1.99
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov (2014) 1.99
Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J Biol Chem (2005) 1.89
Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer (2013) 1.80
mTOR Signaling. Cold Spring Harb Perspect Biol (2012) 1.79
MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet (2012) 1.70
A genome-wide visual screen reveals a role for sphingolipids and ergosterol in cell surface delivery in yeast. Proc Natl Acad Sci U S A (2005) 1.67
A Central role for mTOR in lipid homeostasis. Cell Metab (2013) 1.57
The TSC-mTOR pathway regulates macrophage polarization. Nat Commun (2013) 1.57
Functional genomics identifies TOR-regulated genes that control growth and division. Curr Biol (2006) 1.57
Cell microarrays and RNA interference chip away at gene function. Nat Genet (2005) 1.56
Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c. Cell Metab (2011) 1.55
Microarrays of small molecules embedded in biodegradable polymers for use in mammalian cell-based screens. Proc Natl Acad Sci U S A (2004) 1.48
Calorie restriction in humans inhibits the PI3K/AKT pathway and induces a younger transcription profile. Aging Cell (2013) 1.48
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol (2014) 1.41
p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet (2009) 1.41